g0d4ather-shutterstock-com-amgen-

g0d4ather / Shutterstock.com

3 October 2016Americas

Amgen and Arrowhead agree RNAi development deal

Biopharmaceutical company Amgen and drug manufacturer Arrowhead Pharmaceuticals have entered into two agreements to develop and commercialise RNA interference (RNAi) therapies for cardiovascular disease.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More features

Chinese biotech takes out US rival’s nucleic acid patent at PTAB

Attorney v examiner: Navigating patenting's AI tools ‘arms race’

Lewis Roca promotes tech expert to managing partner

Panitch Schwarze brings in molecular biologist

US targets ‘product hopping’ with biologic litigation curbs

UPC confirms validity of Edwards Lifesciences heart valve tech patent

ITC concludes row over biotech lab equipment between US and German rivals

UKIPO launches ‘revolutionary’ patent filing and AI tool